drugset / Trial / NCT02484911

Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

NCT02484911

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy.

Timeline

Start
2015-05
Primary completion
2016-09
Completion
2017-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg Oral
Subject Olanzapine Small molecule 5 mg Oral
Background Dexamethasone Small molecule 3.75 mg Intravenous
Background Palonosetron Other / unclassified 0.25 mg Intravenous